Two combined rotavirus vaccination regimens were evaluated in a gnotobiotic pig model of rotavirus infection and disease and were compared to previously tested rotavirus vaccination regimens. The first (AttHRV/VLP2؋) involved oral inoculation with one dose of attenuated (Att) Wa human rotavirus (HRV), followed by two intranasal (i.n.) doses of a rotavirus-like particle (2/6-VLPs) vaccine derived from Wa (VP6) and bovine RF (VP2) rotavirus strains. The 2/6-VLPs were coadministered with a mutant Escherichia coli heat-labile toxin, LT-R192G (mLT) adjuvant. For the second regimen (VLP2؋/AttHRV), two i.n. doses of 2/6-VLPs؉mLT were given, followed by one oral dose of attenuated Wa HRV. To compare the protective efficacy and immune responses induced by the combined vaccine regimens with individual rotavirus vaccine regimens, we included in the experiments the following vaccine groups: one oral dose of attenuated Wa HRV (AttHRV1؋ and Mock2؋/AttHRV, respectively), three oral doses of attenuated Wa HRV (AttHRV3؋), three i.n. doses of 2/6-VLPs plus mLT (VLP3؋), three i.n. doses of purified double-layered inactivated Wa HRV plus mLT (InactHRV3؋), mLT alone, and mock-inoculated pigs. The isotype, magnitude, and tissue distribution of antibody-secreting cells (ASCs) in the intestinal and systemic lymphoid tissues were evaluated using an enzyme-linked immunospot assay. The AttHRV/VLP2؋ regimen stimulated the highest mean numbers of intestinal immunoglobulin A (IgA) ASCs prechallenge among all vaccine groups. This regimen induced partial protection against virus shedding (58%) and diarrhea (44%) upon challenge of pigs with virulent Wa HRV. The reverse VLP2؋/AttHRV regimen was less efficacious than the AttHRV/VLP2؋ regimen in inducing IgA ASC responses and protection against diarrhea (25% protection rate) but was more efficacious than VLP3؋ or InactHRV3؋ (no protection). In conclusion, the AttHRV/VLP2؋ vaccination regimen stimulated the strongest B-cell responses in the intestinal mucosal immune system at challenge and conferred a moderately high protection rate against rotavirus disease, indicating that priming of the mucosal inductive site at the portal of natural infection with a replicating vaccine, followed by boosting with a nonreplicating vaccine at a second mucosal inductive site, may be a highly effective approach to stimulate the mucosal immune system and induce protective immunity against various mucosal pathogens.
Rotavirus infections are the most important cause of severe infantile gastroenteritis (19) , accounting for more than 125 million cases of diarrhea and an estimated 600,000 to 870,000 deaths annually worldwide (7) . In the United States, rotavirus infections cause 500,000 physician visits and 50,000 hospitalizations each year (16) . Although the worldwide impact of this virus on public health has led to major efforts to develop vaccines to control rotaviral disease, many difficulties have been encountered. All rotavirus vaccines assessed in human infants were live oral vaccines targeting induction of protective intestinal immunity against severe diarrhea, but their efficacy was variable (7) . A licensed live oral reassortant rotavirus vaccine was withdrawn due to an association with cases of intussusception after the first dose (1) . For these reasons, alternative vaccines and vaccination approaches are being evaluated, e.g., nonreplicating vaccines and extraintestinal immunization routes, by using adult mouse and rabbit models of rotavirus infection and a neonatal gnotobiotic pig model of rotavirus infection and diarrhea. The protective efficacy against rotavirus shedding of alternative vaccines tested in adult mice or rabbits (inactivated virus [27] and 2/6-VLPs [10, 31, 32] ) did not predict the protective efficacy against disease observed in gnotobiotic pigs (50, 52) in which minimal or no protection against virus shedding and diarrhea occurred. Differences in the pathogenicity of rotavirus infections in adult mice (virus shedding, but no intestinal lesions or disease) (11, 21, 48) compared to neonatal pigs (virus shedding, intestinal lesions, and diar-rhea induced by HRV) (38, 39, 40) may have contributed to the different results observed in mice versus pigs.
Rotaviruses replicate in the small intestinal enterocytes of infants and neonatal pigs causing villous atrophy and diarrhea (39) . Fecal or intestinal immunoglobulin A (IgA) antibody responses have been most consistently associated with protective immunity in naturally infected humans and in gnotobiotic pigs experimentally infected with HRV (12, 22, 45, 51, 53) . For enteric viral vaccines such as rotavirus, oral immunization with live virus appears to be the most effective way to induce intestinal IgA antibody responses, because it mimics the natural route of infection and viral replication amplifies the magnitude of antigen-stimulation in the intestine. In our previous studies, oral inoculation of gnotobiotic pigs with 2 or 3 doses of attenuated Wa human rotavirus (HRV) conferred partial protection against virus shedding (19 and 67%, respectively) and diarrhea (34 and 63%, respectively) upon virulent Wa HRV challenge (51, 53) . The protection rates of the three-dose-attenuated Wa HRVs in gnotobiotic pigs concur with the protection rates against mild to severe rotavirus diarrhea conferred in children by three doses of oral tetravalent rotavirus vaccines in the United States (50 to 69%) (7, 51) .
The effects of a combined oral and intraperitoneal vaccination regimen were examined in mice (26) . Oral inoculation of mice with live heterologous rhesus rotavirus, followed by intraperitoneal inoculation with inactivated homologous murine rotavirus (EDIM), elicited a small but significant enhancement of serum IgG and IgA and fecal IgA antibody responses upon challenge with EDIM rotavirus (postinoculation day [PID] 49) and a reduction in virus shedding after challenge. The authors of that study suggested that these enhanced antibody responses and partial protection observed were additive (26) . For nonreplicating vaccines such as inactivated rotaviruses or virus-like particles (2/6-VLPs), intranasal (i.n.) immunization with effective mucosal adjuvants induces higher intestinal IgA antibody responses in adult mice than immunization by the oral or parenteral routes (17, 27, 32) . The use of combined oral and i.n. vaccination routes stimulates multiple mucosal inductive sites, i.e., both gut-associated lymphoid tissues (GALT) and nasal-associated lymphoid tissues (NALT) in contrast to the individual oral or i.n. vaccination routes alone. This combined approach has not been reported previously in rotavirus vaccine studies. Our hypothesis was that by exploiting the advantages of multiple mucosal immunization routes (i.e., oral and i.n.) and vaccine types (replicating virus and nonreplicating VLPs), a combined vaccination regimen may optimally stimulate the mucosal immune system and increase the protective efficacy of rotavirus vaccines.
The objectives of the present study were (i) to assess whether immunization of gnotobiotic pigs with sequential oralattenuated Wa HRV and i.n. 2/6-VLPsϩmLT vaccines confers greater protection against rotavirus infection and diarrhea compared to the individual vaccines; ( ii) to determine whether the sequence of immunization by oral priming with live attenuated HRV, followed by i.n. boosting with recombinant 2/6-VLPs versus i.n. priming with 2/6-VLPs followed by oral boosting with live attenuated HRV, plays a role in the induction of protection and intestinal and systemic antibody-secreting cell (ASC) responses to Wa HRV; and (iii) to examine how the combination of oral and i.n. mucosal immunization routes and vaccine types influences the magnitude, isotype, and tissue distribution of virus-specific ASCs in gnotobiotic pigs.
MATERIALS AND METHODS
Virus. The attenuated (cell culture-adapted) Wa strain HRV propagated and titered in monkey kidney (MA104) cells was used for the inoculation of pigs and the ELISPOT assay (50, (51) (52) (53) . The virulent Wa HRV (intestinal contents from infected gnotobiotic pigs) used for challenge contained 10 6 50% infectious doses (ID 50 ) (50, 52, 53) . To prepare the double-layered inactivated Wa HRV inoculum, the attenuated Wa HRV was treated twice with 50 mM EDTA (25) , purified by ultracentrifugation on CsCl gradients (9) , and inactivated by using 0.01 M binary ethylenimine as previously described (2, 15) . The inactivated Wa HRV preparation was examined using immunoelectron microscopy to verify the size and morphologic integrity of the rotavirus particles (36) . A plaque assay and a cell culture immunofluorescence infectivity (CCIF) assay (3, 49) were performed to assure complete inactivation. Western blot using hyperimmune serum against Wa HRV and monoclonal antibodies against homotypic VP4 and VP7 was performed to confirm the absence of VP4 and VP7 antigens in the doublelayered inactivated HRV preparation as previously described (13) .
VLPs and adjuvant. The 2/6-VLPs (VP2 from RF bovine rotavirus and VP6 from virulent Wa HRV) were produced by coexpression of recombinant baculoviruses containing the VP2 and VP6 genes in Spodoptera frugiperda 9 insect cells (13, 50) . The 2/6-VLPs were purified by using CsCl gradient ultracentrifugation (13) . The protein concentration and integrity of the 2/6-VLPs were determined as previously described (50) . The mLT adjuvant was provided by J. Clements (Tulane University Medical Center, New Orleans, La.) and used at 5 g per dose in gnotobiotic pigs as described in a previous study (50) .
Inoculation of gnotobiotic pigs. Near-term pigs were derived by hysterectomy and maintained in isolation units as described previously (28) . Pigs were assigned to nine groups as follows: (i) one oral dose of attenuated Wa HRV, followed by 2 i.n. doses of 2/6-VLPsϩmLT (AttHRV/VLP2ϫ); (ii) two i.n. doses of 2/6-VLPsϩmLT, followed by one oral dose of attenuated Wa HRV (VLP2ϫ/ AttHRV); (iii) three oral doses of attenuated Wa HRV (AttHRV3ϫ); (iv) one oral dose of attenuated Wa HRV, followed by two i.n. doses of mLT alone (AttHRV1ϫ); (v) two i.n. doses of mLT alone, followed by one oral dose of attenuated Wa HRV (Mock2ϫ/AttHRV1ϫ); (vi) three i.n. doses of purified double-layered inactivated Wa HRV plus mLT (InactHRV3ϫ); (vii) three i.n. doses of 2/6-VLPs plus mLT (VLP3ϫ); (viii) three i.n. doses of mLT alone (mLT); and (ix) mock-inoculated controls (Mock).
(i) Oral inoculation with attenuated Wa HRV followed by i.n. boosting with 2/6-VLPs؉mLT (AttHRV/VLP2؋). At 3 to 5 days of age, pigs were given 5 ml of 100 mM NaHCO 3 to reduce gastric acidity and then inoculated orally with ϳ5 ϫ 10 7 fluorescent focus-forming units (FFU) of attenuated Wa HRV (AttHRV/ VLP2ϫ and AttHRV1ϫ pigs) or 5 ml of minimal essential medium (MEM) diluent (mLT and Mock control pigs). At PIDs 10 and 20, the AttHRV/VLP2ϫ pigs were inoculated i.n. with 250 g of 2/6-VLPs plus 5 g of mLT. The VLPs and mLT were diluted in 0.5 ml of sterile TNC buffer (10 mM Tris-HCl, pH 7.5; 140 mM NaCl; 10 mM CaCl 2 ) and slowly administered by drops into the pig's nostrils. The AttHRV1ϫ and mLT control pigs were similarly inoculated i.n. twice or three times, respectively, with 5 g of mLT alone. Mock control pigs were given an equal volume of TNC buffer.
(ii) i.n. inoculation with 2/6-VLPs؉mLT, followed by oral boosting with attenuated Wa HRV (VLP2؋/AttHRV). At 3 to 5 days of age and 10 days later, pigs were inoculated i.n. with 250 g of 2/6-VLPs plus 5 g of mLT in 0.5 ml of TNC buffer. The Mock2ϫ/AttHRV pigs were given an equal volume of TNC buffer. At PID 21 (post-first inoculation), the VLP2ϫ/AttHRV and Mock2ϫ/AttHRV pigs were inoculated orally with ϳ5 ϫ 10 7 FFU of the cell-culture-adapted attenuated Wa HRV in 5 ml of MEM (Gibco/Life Technologies, Grand Island, N.Y.). Pigs were given 5 ml of 100 mM NaHCO 3 orally to reduce gastric acidity 10 min prior to administration of the virus.
(iii) Other vaccine groups. Three oral doses of attenuated Wa HRV, three i.n. doses of 2/6-VLPsϩmLT, or three i.n. doses of purified double-layered inactivated Wa HRVϩmLT were given to pigs in the same manner and dosages as for the AttHRV/VLP2ϫ or VLP2ϫ/AttHRV pigs. Because of the small numbers of pigs in these groups, protection data and immune responses from the AttHRV3ϫ and VLP3ϫ pigs were pooled with the data from the pigs treated with the same vaccine regimens in our previous studies (50, 51) .
Assessment of protection. At PID 28, 7 days after the last inoculation, subsets of pigs from AttHRV/VLP2ϫ, VLP2ϫ/AttHRV, AttHRV3ϫ, AttHRV1ϫ, VLP3ϫ, and InactHRV groups and all pigs from the Mock2ϫ/AttHRV and mLT and Mock control groups were challenged orally with ϳ10 6 ID 50 of virulent Wa HRV (47) . This challenge dose was previously determined (47) to cause diarrhea in nearly 100% of control pigs upon challenge. Rectal swabs were collected for 6 days after challenge for assessment of diarrhea and virus shedding. Daily diarrhea scores were based on fecal consistency as follows: 0, normal; 1, pasty; 2, semiliquid; and 3, liquid. Pigs with daily fecal consistency scores of Ն2 were considered diarrheic. The mean cumulative fecal score was calculated as the mean of the sum of the daily fecal scores in each group from postchallenge day (PCD) 1 to 6. Infectious Wa HRV and viral antigen in rectal swab fluids were assessed by a cell culture immunofluoresence (CCIF) infectivity assay (3) and by an antigen-capture enzyme-linked immunosorbent assay, respectively, as described previously (18, 37) .
Isolation of MNC and ELISPOT assay. Subsets of pigs were euthanized at the selected time points, and the small intestines (duodenum and ileum), mesenteric lymph nodes (MLN), spleen, and peripheral blood lymphocytes (PBL) were collected at PID 28 (PCD 0) and at PID 35 (PCD 7) for the isolation of mononuclear cells (MNC) as described previously (50, 52, 53) . Isotype-specific enzyme-linked immunospot (ELISPOT) assays for detecting IgM, IgA, and IgG ASCs to Wa HRV were performed to evaluate effector B-cell responses in the lymphoid tissues (50, 52, 53) .
Virus-neutralizing antibody titers. Serum samples from all nine groups of pigs in this study and from pigs receiving a single oral dose of virulent Wa HRV from a previous study (51) were tested for virus-neutralizing antibody titers by using a plaque reduction assay as described previously (37) .
Statistical analysis. Fisher's exact test (SAS Institute, Inc., Cary, N.C.) was used to compare proportions of pigs with diarrhea and virus shedding among groups. One-way analysis of variance (ANOVA), followed by Duncan's multiplerange test, were used to compare mean duration of virus shedding and diarrhea, mean peak titers of virus shed, and mean cumulative scores. The ASC numbers were compared among or within groups using the Kruskal-Wallis rank sum (nonparametric) test. Statistical significance was assessed at P Ͻ 0.05 for all comparisons.
RESULTS
Protection against virulent Wa HRV challenge conferred by the combined vaccination regimens. Protection levels (assessed by the reduction of virus shedding and diarrhea) conferred by the two combined vaccination regimens were compared with controls and the other individual vaccines. Protection data were pooled between AttHRV1ϫ and Mock2ϫ/AttHRV groups and mLT and Mock control groups, respectively, for statistical analysis because there were no significant differences between the corresponding groups ( Table 1 ). All pigs in the mLT and Mock control groups shed virus, and 89% of the pigs developed diarrhea upon challenge with virulent Wa HRV. The vaccination regimens of both AttHRV/VLP2ϫ and VLP2ϫ/ AttHRV induced partial protection against virus shedding and diarrhea upon challenge with virulent Wa HRV ( Table 1) . Pigs in the AttHRV/VLP2ϫ group had significantly reduced virus shedding (42%) and diarrhea (50%) rates compared to the mLT and Mock controls. The pigs that developed virus shedding and diarrhea in the AttHRV/VLP2ϫ group had a significantly shorter mean duration of virus shedding, significantly reduced mean cumulative fecal scores (indicating reduced severity of disease), and lower mean peak titers of virus shed with a shorter mean duration of diarrhea (half as long) compared to the mLT and Mock controls. The protection rates conferred by the AttHRV/VLP2ϫ regimen were comparable with, although slightly lower than, the protection rates conferred by the AttHRV3ϫ regimen (protection rates of 58 versus 67% for shedding and 44 versus 63% for diarrhea, respectively) ( Table  1) . However, among the AttHRV/VLP2ϫ pigs that shed virus after challenge, the mean duration of virus shedding was 1 day only, which was shorter than the mean for the AttHRV3ϫ pigs that shed virus (Table 1) .
In contrast, the VLP2ϫ/AttHRV regimen conferred lower protection rates against virus shedding (17%) and diarrhea (25%) ( Table 1) . A single oral dose of attenuated Wa HRV, given at 3 to 5 days of age or at 7 days before challenge, induced a 33% protection rate against diarrhea; however, all of the pigs in this group shed virus after challenge. Pigs in the VLP2ϫ/AttHRV and one-oral-dose-attenuated Wa HRV groups had significantly lower mean cumulative fecal scores, shorter mean duration of virus shedding and diarrhea, and lower mean peak virus shedding titers, although not significantly so for the latter two parameters, compared to the mLT and Mock controls. Three i.n. doses of 2/6-VLPsϩmLT or double-layered inactivated Wa HRV conferred no protection against either virus shedding or diarrhea. The severity of virus shedding and diarrhea in the pigs from these two groups were comparable to those of the mLT and Mock controls (Table 1) .
Rotavirus-specific ASC responses. The rotavirus-specific ASC responses in the intestinal and systemic lymphoid tissues of pigs inoculated with the two combined vaccine regimens (AttHRV/VLP2ϫ and VLP2ϫ/AttHRV), one and three oral doses of attenuated Wa HRV (AttHRV1ϫ, Mock2ϫ/AttHRV, and AttHRV3ϫ), three i.n. doses of 2/6-VLPs (VLP3ϫ), and mLT alone (mLT control) are depicted in Fig. 1 and 2 . The rotavirus-specific ASCs are presented as mean numbers of ASC per 5 ϫ 10 5 MNC. To assess whether the combined vaccine regimens elicited significantly higher ASC responses in the intestinal and systemic lymphoid tissues compared to the oral attenuated or i.n. VLP vaccines, statistical comparisons were made pairwise between the AttHRV/VLP2ϫ or VLP2ϫ/ AttHRV groups and the other vaccine groups. Table 2 highlights the ASC numbers for the combined vaccine groups AttHRV/VLP2ϫ and VLP2ϫ/AttHRV.
(i) Prechallenge. Before challenge, no virus-specific ASCs were detected in the mLT control group (data not shown). The combined vaccine regimens (AttHRV/VLP2ϫ or VLP2ϫ/ AttHRV) induced higher virus-specific IgM and IgA ASC responses in all lymphoid tissues, but especially in the intestinal tissues, compared to the individual vaccine regimens VLP3, AttHRV1ϫ, and AttHRV3ϫ; the AttHRV/VLP2ϫ regimen induced higher IgM, IgA (significantly higher), and IgG ASC responses in the intestinal lymphoid tissues than the VLP2ϫ/ AttHRV regimen at PID 28 and PCD 0 ( Fig. 1 and Table 2 ). The numbers of IgM ASCs in the duodenum and ileum of the AttHRV/VLP2ϫ pigs were significantly higher than those of the VLP3ϫ (18-to 23-fold), AttHRV1ϫ (18-to 57-fold), and AttHRV3ϫ (25-to 47-fold) pigs (Fig. 1A) . The numbers of IgA ASCs in the duodenum, ileum, and MLN of the AttHRV/ VLP2 pigs were significantly higher than those of the VLP3ϫ (11-to 106-fold), AttHRV1ϫ (11-to 100-fold), AttHRV3ϫ (8-to 53-fold), and VLP2ϫ/AttHRV (5-to 13-fold) pigs (Fig. 1) . The numbers of IgG ASCs in the duodenum, ileum, and MLN of AttHRV/VLP2ϫ pigs were also higher or significantly higher than those of the AttHRV1ϫ (12-to 54-fold), AttHRV3ϫ (7-to 36-fold), and VLP2ϫ/AttHRV (3-to 19-fold) pigs. The numbers of IgG ASCs in the AttHRV/VLP2ϫ pigs were comparable to those of the VLP3ϫ group in the duodenum and ileum, but they were significantly higher in the MLN (7-fold), spleen (3.5-fold), and peripheral blood (at least 3-fold) than those of the VLP3ϫ pigs at PID 28 and PCD 0 (Fig. 1) . In contrast to the higher or significantly higher numbers of IgM, IgA, and IgG ASCs in the intestinal lymphoid tissues induced by the AttHRV/VLP2ϫ regimen compared to the VLP2ϫ/ AttHRV regimen, the numbers of ASCs induced by the AttHRV/VLP2ϫ regimen in the spleen and peripheral blood were similar to or lower than those induced by the VLP2ϫ/ AttHRV regimen at PID 28 and PCD 0 ( Table 2) .
(ii) Postchallenge. After challenge, although the mean numbers of IgA and IgG ASCs in the AttHRV3ϫ pigs were highest in most of the tissues, the mean numbers of IgA ASCs in all tissues of the AttHRV/VLP2ϫ pigs remained higher (1.4-to 9-fold) than those of the VLP3ϫ, AttHRV1ϫ, and VLP2ϫ/ AttHRV pigs, except in the MLN and PBL of the VLP3ϫ pigs, in which the IgA ASC numbers were similar to those of the AttHRV/VLP2ϫ pigs at PID 35 and PCD 7 (Fig. 2) . The numbers of IgA ASCs of the AttHRV/VLP2ϫ pigs were significantly higher (12-to 31-fold) in the duodenum and ileum compared to those of the Mock2/AttHRV and mLT control pigs. Similarly, the mean numbers of IgG ASCs of the AttHRV/ VLP2ϫ pigs were significantly higher (8-to 95-fold) in the duodenum, ileum, and MLN compared to these two control groups. The numbers of IgG ASCs of the AttHRV/VLP2ϫ pigs were also higher (in the ileum) or significantly higher (in the duodenum) than those of the VLP3ϫ, AttHRV1ϫ, and VLP2ϫ/AttHRV pigs.
Pigs that received three i.n. doses of double-layered inactivated Wa HRV (InactHRV3ϫ) developed none or low numbers of IgM, IgA, and IgG ASCs in the intestinal and systemic lymphoid tissues (0 to 2.5 ASC per 5 ϫ 10 5 MNC) at the time of challenge and lower numbers of IgA and IgG ASCs after challenge (6 to 18 per 5 ϫ 10 5 MNC) (data not shown) compared to the other vaccine groups.
VN antibody responses in serum. The virus-neutralizing (VN) geometric mean titer (GMT) in the serum of gnotobiotic pigs after inoculation and challenge are summarized in Table  3 . At PIDs 10 and 21, the VN GMTs of the AttHRV/VLP2ϫ pigs were statistically similar to those of the virulent Wa HRVinoculated pigs (VRHRV1ϫ) and the AttHRV3ϫ and AttHRV1ϫ pigs but were significantly higher than those of InactHRV3ϫ, VLP2ϫ/AttHRV, Mock2ϫ/AttHRV, VLP3ϫ, and the mLT and Mock control pigs. At PID 28 and PCD 0, although the VN GMT in the AttHRV/VLP2ϫ pigs was significantly lower than that of the AttHRV3ϫ pigs, it was still significantly higher than that of the InactHRV3ϫ, VLP2ϫ/ AttHRV, Mock2ϫ/AttHRV, VLP3ϫ, and control pigs. The VN GMT in the AttHRV/VLP2ϫ group was about 2.3-fold higher (but not significantly) than that of the AttHRV1ϫ pigs. After challenge, the AttHRV3ϫ and AttHRV/VLP2ϫ pigs developed significantly higher VN GMTs in the serum than all other groups; however, the VN GMTs in the VLP3ϫ and InactHRV3ϫ pigs were similar to the VN GMTs of mLT and Mock control pigs.
DISCUSSION
The risk of intussusception in infants using a live oral rotavirus vaccine prompted us to explore alternative vaccination routes and combined live and nonreplicating vaccines. The combined vaccine regimen with multiple vaccine types and routes is a new rotavirus vaccine approach that we explored in the present study. By taking advantage of both the oral-live and the i.n.-2/6-VLP vaccination approaches, the AttHRV/VLP2ϫ vaccination regimen stimulated the highest intestinal IgA effector B-cell responses and a high protection rate against HRV infection and diarrhea in gnotobiotic pigs. Interestingly, of the combined immunization routes, oral priming followed by i.n. boosting, and vaccine types, live attenuated Wa HRV for priming followed by 2/6-VLPsϩmLT for boosting, was more effective in stimulating intestinal IgA ASC responses than each individual vaccine (AttHRV1ϫ, -2ϫ, or -3ϫ or VLP3ϫ) or the converse combined VLP2ϫ/AttHRV regimen. The VLP2ϫ/ AttHRV regimen conferred only a low protection rate (19%) against diarrhea, which was higher than that with VLP3ϫ or InactHRV3ϫ (0%) but lower than that with AttHRV3ϫ (67%) and AttHRV/VLP2ϫ (44%). In contrast, the AttHRV/ VLP2ϫ vaccine sequence induced the highest mean numbers of intestinal IgA ASCs compared to all other vaccination approaches tested in gnotobiotic pigs, including one to three oral doses of live attenuated Wa HRV, two or three intramuscular doses of inactivated Wa HRV with incomplete Freund adjuvant, and two or three i.n. doses of SA11 or Wa 2/6-VLPs with or without mLT (50, 51, 52, 53) . One possible explanation for why the AttHRV/VLP2 regimen inducted the highest intestinal IgA ASC responses may be the sequence of stimulation of the mucosal inductive sites, e.g., first the GALT and then NALT, in combination with the initial priming with intact live virus (which mimics natural infection and amplifies the virus dose), followed by boosting with 2/6-VLPsϩmLT. After oral inoculation of pigs with attenuated Wa HRV, the rotaviral antigens are presumably taken up via GALT, e.g., ileal and jejunal Peyer's patches (8 . These sites would include the lamina propria of the intestine in particular, but, in addition, after trafficking via the common mucosal immune system, these sites could also include mucosal tissues in the respiratory tract (30, 35) . The intestinal Peyer's patches have previously been reported to be efficient inductive sites for precursors of IgA effector B cells that populate distant mucosal lymphoid tissues, including the lamina propria of the upper respiratory tract (6) . The rotavirus-sensitized precursor B cells in the upper respiratory tract (e.g., the lymphoid tissues in nasopharyngeal tonsils) may then be restimulated by the 2/6-VLPsϩmLT from the i.n. boosting, undergoing clonal expansion and maturation into effector B cells. In addition, priming of naive B cells in the NALT may have occurred after the sequential i.n. inoculations. The effector cells may then migrate into the intestines via the blood circulation due to the gut-seeking properties (interaction of intestinal homing receptor ␣4␤7 integrin on the ASCs and its ligand mucosal addressin cell adhesion molecule, MAdCAM-1, on postcapillary high endothelial venules) of GALT-derived primed B cells and the homing heterogeneity of NALT-derived primed B cells (6, 33) . Researchers (33) reported that a large majority of circulating ASCs induced by i.n. inoculation of humans with recombinant cholera toxin B subunit coexpressed L-selectin and ␣4␤7. Thus, the rotavirus-specific ASCs detected in the intestinal lymphoid tissues after the sequential oral and i.n immunizations could have been generated in the two mucosal inductive sites: GALT and NALT. The dual se- quential inductive sites may have resulted in the higher IgA, IgG, and especially higher IgM ASC numbers detected after the second boosting dose of 2/6-VLPsϩmLT compared to ASC numbers in pigs inoculated with one to three oral doses of attenuated Wa HRV or three i.n doses of 2/6-VLPsϩmLT alone.
Another factor which may have contributed to the higher numbers of ASCs induced by AttHRV/VLP2ϫ is that boosting via the i.n. route avoided the preexisting antibodies stimulated by the prior oral inoculation of attenuated Wa HRV in the intestines. i.n. boosting with two doses of 2/6-VLPsϩmLT elicited higher ASC responses than oral boosting with one or two doses of attenuated Wa HRV in the two-or three-dose oral attenuated Wa HRV regimens (51, 53) . In the latter regimens, the intestinal antibodies induced by primary oral inoculation with live attenuated Wa HRV may have partially neutralized the live virus in the booster doses, limiting replication and the amount of viral antigen available for stimulation. In contrast, boosting with nonreplicating VLPs via an extraintestinal inductive site, the NALT, could prevent interference by the higher levels of local antibodies in the intestine compared to the upper respiratory tract.
Although the intestinal IgA ASC responses were significantly higher at challenge, the protection rate conferred by AttHRV/ VLP2ϫ was slightly lower than that of the AttHRV3ϫ regimen. This finding and our previous findings of the lack of protection of 2/6-VLP vaccines (50) indicate that protective immunity to rotavirus diarrhea in pigs is dependent not only on the location, the magnitude, and the isotypes of antibody but also on the protein specificity (VP4 and VP7 neutralizing antibodies) of the B-cell responses induced. The VLP3ϫ vaccine induced low intestinal IgA and high IgG effector B-cell responses prechallenge. This antibody response, however, did not confer protection against virus shedding and diarrhea upon challenge with virulent Wa HRV. On the other hand, the AttHRV/VLP2ϫ regimen conferred a higher protection rate compared to AttHRV1ϫ or Mock2ϫ/AttHRV, indicating that boosting with 2/6-VLPs did increase the protection rate. Boosting with 2/6-VLPsϩmLT might have "nonspecifically" boosted the primary antibody responses to all of the viral proteins (including VP4 and VP7) induced by the live attenuated Wa HRV, possibly mediated by cross-reactive T helper cells. This idea is also supported by the observation that the VN GMT in the serum of AttHRV/VLP2ϫ pigs was elevated (2.3-fold) compared to that of the AttHRV1ϫ pigs at PID 28 and PCD 0. Similar boosting responses were observed in studies of hepatitis B virus (29) and influenza virus (41) in which T helper cells directed against internal viral capsid proteins can provide cognate help to B cells specific for external viral proteins. However, in contrast to the study of mice (14) , which suggested that primary inoculation with VP6 enhanced the VN antibody responses following challenge, the VN GMTs in the VLP3ϫ or InactHRV3ϫ vaccine-immunized pigs were similar or lower compared to mLT or Mock controls at PCD 7.
Although the AttHRV/VLP2 regimen did not confer a higher rate of protection compared to the AttHRV3ϫ vaccine, The lower level of ASC responses induced by the VLP2ϫ/ AttHRV regimen compared to the AttHRV/VLP2 regimen was possibly due to functional compartmentalization of the mucosal inductive site (NALT) involved in these vaccination approaches (33) . The mucosal immune system has been proposed to be compartmentalized such that lymphocytes preferentially migrate back into tissues where the cells were primed (5, 33, 42) . Investigations of mucosal immunization or experimental infection of rodents and pigs (23, 43, 46) suggest that the migration of B cells induced in NALT and bronchial associated lymphoid tissues (BALT) to the intestinal lamina propria is much less efficient in terms of generating intestinal IgA antibody responses than the extensive mucosal dissemination of GALT-derived B cells (24) . In addition, the much greater mass of GALT inductive sites compared to NALT or BALT in pigs favors the generation of greater B-cell responses (46) . Previous studies of the immunization of women against cholera, an enteric pathogen, suggest that women who received parenteral immunizations with cholera vaccine and who were previously naturally exposed to cholera had significant increases in IgA antibodies in breast milk compared to previously unexposed women (44) . A study of a respiratory Sendai virus vaccine showed that protection was provided by oral immunization of mice only after an i.n. priming dose of the live virus was given (20) . The results of our studies, the cholera natural infection and vaccination (44) , and the respiratory Sendai virus vaccines (20) collectively suggest that priming of the mucosal inductive site at the portal of natural infection with a replicating vaccine may be important for induction of protective immunity when boosting doses are given via a different vaccination route.
Higher IgM, IgA, and especially IgG ASC responses were observed in the spleen and/or the blood of pigs immunized with the VLP2ϫ/AttHRV regimen compared to the AttHRV/ VLP2ϫ regimen. This result is consistent with previous observations of pigs i.n. inoculated with a porcine respiratory coronavirus (PRCV) and challenged orally with transmissible gastroenteritis virus (TGEV) (46) . In this study, immunization via BALT (PRCV infection) induced high systemic ASC responses with low numbers of ASCs in the intestine and provided partial protection against gastroenteritis after challenge with TGEV. In contrast, immunization via GALT (TGEV infection) induced high numbers of IgA ASCs in the intestine and provided complete protection against TGEV disease. It has been suggested that i.n. immunization, in general, is efficient for stimulating systemic immunity (4) and elicits an antibody response with later onset but of longer duration than the oral route (34) .
In conclusion, the combined vaccination routes (oral followed by i.n., with the involvement of GALT and then NALT) and vaccine types (replicating virus followed by nonreplicating VLPs) effectively stimulated the intestinal immune system as indicated by highest ASC responses compared to all other types of vaccines tested and conferred moderately high protection to pigs against rotavirus infection and disease. The protection rate of this regimen may be further improved by using triple-layered 2/4/6/7 VLPs to directly boost the ASC responses to VP4 and VP7 and neutralizing antibodies that were primed by the first dose of live AttHRV, likely achieving a higher protection rate as reported with intact rotavirus (51, 53) . These findings have important implications for the development of new vaccination strategies for various mucosal pathogens. The use of a replicating vaccine to prime the B and T cells in the major inductive site, followed by boosting with a nonreplicating vaccine at a second mucosal inductive site, may be a highly effective approach to stimulate the mucosal immune system and induce protective immunity. b n, number of pigs tested at the time point in each group. The GMTs in the same column with different superscript letters are significantly different (one-way ANOVA [general linear models procedure], followed by Duncan grouping on log 10 transformed titers). GMTs were determined by a plaque reduction assay. All pigs had GMT of Ͻ4 (negative) at PID 0. Titers of Ͻ4 were recorded as 2 for data analysis.
